back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-12-05 19:38 Tx date 2024-11-26 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
+1,968,611 vol |
19,370,227 | |
| Filed 2024-12-05 19:37 Tx date 2024-11-26 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Convertible Preferred Shares Class A Preference Shares
11 - Acquisition or disposition carried out privately
|
-250,000 vol |
0 | |
| Filed 2024-12-05 19:32 Tx date 2024-11-26 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
+295,291 vol |
1,170,923 | |
| Filed 2024-12-05 19:31 Tx date 2024-11-26 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Preferred Shares Class A Preference Shares
11 - Acquisition or disposition carried out privately
|
-37,500 vol |
0 | |
| Filed 2024-12-05 15:39 Tx date 2024-12-02 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Holder: Peter W. Lewis Inc. (Indirect Ownership)
|
Common Shares
36 - Conversion or exchange
|
+277,500 vol |
696,577 | |
| Filed 2024-12-05 15:38 Tx date 2024-12-02 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Holder: Peter W. Lewis Inc. (Indirect Ownership)
|
Convertible Preferred Shares Class A Preference Shares
36 - Conversion or exchange
|
-37,500 vol |
0 | |
| Filed 2023-08-25 17:06 Tx date 2023-08-16 |
$RP
RepliCel Life Sciences Inc. |
Kwok, David
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
150,000 | ||
| Filed 2023-08-25 17:05 Tx date 2023-08-16 |
$RP
RepliCel Life Sciences Inc. |
Kwok, David
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-08-25 17:04 Tx date 2023-08-16 |
$RP
RepliCel Life Sciences Inc. |
Kwok, David
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-05-12 11:24 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Boddington, Gary
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+75,000 vol |
325,000 | |
| Filed 2023-05-10 17:46 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
780,000 | |
| Filed 2023-05-10 12:23 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
1,155,000 | |
| Filed 2023-05-10 11:57 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Austring, Ben
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+250,000 vol |
670,000 | |
| Filed 2023-05-10 11:53 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$11,250
+75,000 vol $0.15 each |
205,000 | |
| Filed 2023-05-10 11:53 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
650,000 | |
| Filed 2023-05-10 11:43 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
McElwee, Kevin
3 - 10% Security Holder of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+250,000 vol |
600,000 | |
| Filed 2023-03-14 18:16 Tx date 2023-03-14 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$402,150
+2,010,750 vol $0.20 each |
4,861,750 | |
| Filed 2023-03-14 18:16 Tx date 2023-03-14 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$402,150
+4,021,500 vol $0.10 each |
10,034,537 | |
| Filed 2023-03-14 18:14 Tx date 2023-03-14 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$404,250
+2,021,250 vol $0.20 each |
6,744,776 | |
| Filed 2023-03-14 18:13 Tx date 2023-03-14 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$404,250
+4,042,500 vol $0.10 each |
17,401,616 |